Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: First clinical experience and evidence of an immune response

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Rüttinger, Dominik ^a   van den Engel, Natasja K ^a   Winter, Hauke ^a   Schlemmer, Marcus ^a   Pohla, Heike ^b,c   Grützner, Stefanie ^a   Wagner, Beate ^a   Schendel, Dolores J ^c   Fox, Bernard A ^d   Jauch, Karl Walter ^a   Hatz, Rudolf A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; T6 ANTIGEN; TUMOR CELL VACCINE; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER STAGING; CARDIOTOXICITY; CASE REPORT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTINUOUS INFUSION; DELAYED HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FATIGUE; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; FLUORESCENCE ACTIVATED CELL SORTING; GASTROINTESTINAL TOXICITY; GRANULOCYTE; HEMOSTASIS; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INJECTION SITE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LEUKAPHERESIS; LIVER TOXICITY; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NATURAL KILLER CELL; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; OSMOTIC MINIPUMP; PATIENT MONITORING; PERICARDITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PNEUMOCYSTIS PNEUMONIA; PUNCH BIOPSY; SIDE EFFECT; SKIN TEST; T LYMPHOCYTE SUBPOPULATION; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VASCULITIS; BIOPSY; BLOOD CELL COUNT; IMMUNITY; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MONONUCLEAR CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOGRAPHY; THORAX RADIOGRAPHY; VACCINATION;

ADJUVANTS, PHARMACEUTIC; AGED; BIOPSY; BLOOD CELL COUNT; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRADERMAL; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; LYMPHOPENIA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIOGRAPHY, THORACIC; VACCINATION;

EID: 35348883568     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-43     Document Type: Article

References (29)

1. Dranoff G Jaffee E Lazenby A Golumbek P Levitsky H Brose K Jackson V Hamada H Pardoll D Mulligan RC Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 1993, 90:3539-3543 46336 8097319 10.1073/ pnas.90.8.3539
2. Salgia R Lynch T Skarin A Lucca J Lynch C Jung K Hodi FS Jaklitsch M Mentzer S Swanson S Lukanich J Bueno R Wain J Mathisen D Wright C Fidias P Donahue D Clift S Hardy S Neuberg D Mulligan R Webb I Sugarbaker D Mihm M Dranoff G Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma J Clin Oncol 2003, 21:624-630 10.1200/ JCO.2003.03.091 12586798
3. Nemunaitis J Sterman D Jablons D Smith JW Fox B Maples P Hamilton S Borellini S Lin A Morali S Hege K Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer J Natl Cancer Inst 2004, 96:326-331 14970281
4. Smyth M Godfrey D Trapani J A fresh look at tumor immunosurveillance and immunotherapy Nat Immunol 2001, 2:293-299 10.1038/86297 11276199
5. Levitsky HI Augmentation of host immune responses to cancer: Overcoming the barrier of tumor antigen-specific T-cell tolerance Cancer J 2000, 6:S281-290 10874499
6. O'Brien SM Kantarjian HM Cortes J Beran M Koller CA Giles FJ Lerner S Keating M Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia J Clin Oncol 2001, 19:1414-1420 11230486
7. Santini G Nati S Spriano M Gallamini A Pierluigi D Congiu AM Truni M Rubagotti A Chisesi T Vimercati R Rossi E Sertoli MR Mattei D Marino G Gobbi M Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma Haematologica 2001, 86:282-286 11255275
8. Dudley ME Wunderlich JR Robbins PF Yang JC Hwu P Schwartzentruber DJ Topalian SL Sherry R Restifo NP Hubicki AM Robinson MR Raffeld M Duray P Seipp CA Rogers-Freezer L Morton KE Mavroukakis SA White DE Rosenberg SA Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 2002, 298:850-854 1764179 12242449 10.1126/science.1076514
9. Dummer W Niethammer AG Baccala R Lawson BR Wagner N Reisfeld RA Theofilopoulos AN T cell homeostatic proliferation elicits effective antitumor autoimmunity J Clin Invest 2002, 110:185-192 151053 12122110 10.1172/JCI200215175
10. Asavaroengchai W Kotera Y Mule JJ Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery Proc Natl Acad Sci USA 2002, 99:931-936 117408 11792864 10.1073/ pnas.022634999
11. Machiels JP Reilly RT Emens LA Ercolini AM Lei RY Weintraub D Okoye FI Jaffee EM Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Res 2001, 61:3689-3697 11325840
12. Ma J Urba WJ Si L Wang Y Fox BA Hu HM Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution Eur J Immunol 2003, 33:2123-2132 10.1002/ eji.200324034 12884286
13. Hu HM Poehlein CH Urba WJ Fox BA Development of antitumor immune responses in reconstituted lymphopenic hosts Cancer Res 2002, 62:3914-3919 12124318
14. FACS core facility http://facs.scripps.edu
15. Butts C Murray N Maksymiuk A Goss G Marshall E Soulieres D Cormier Y Ellis P Price A Sawhney R Davis M Mansi J Smith C Vergidis D Ellis P MacNeil M Palmer M Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer J Clin Oncol 2005, 23:6674-6681 10.1200/JCO.2005.13.011 16170175
16. Atanackovic D Altorki NK Stockert E Williamson B Jungbluth AA Ritter E Santiago D Ferrara CA Matsuo M Selvakumar A Dupont B Chen YT Hoffman EW Ritter G Old LJ Gnjatic S Vaccine-induced CD4+ T cell response to MAGE-3 Protein in Lung Cancer Patients J Immunol 2004, 172:3289-3296 14978137
17. Vansteenkiste J Zielinski M Dahabre J Linder A Malinowski W Jassem J Lopez-Brea M Passlick B Lehmann F Brichard V Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected non-small cell lung cancer (NSCLC) J Clin Oncol 2006, 24(Suppl):7019
18. Borrello I Sotomayor EM Rattis FM Cooke SK Gu L Levitsky HI Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines Blood 2000, 95:3011-3019 10807763
19. Maine GN Mule JJ Making room for T cells J Clin Invest 2002, 110:157-159 151072 12122106 10.1172/JCI200216166
20. Ma J Poehlein CH Jensen SM LaCelle MG Moudgil TM Ruttinger D Haley D Goldstein MJ Smith JW 3rd Curti B Ross H Walker E Hu HM Urba WJ Fox BA Manipulating the host response to autologous tumour vaccines Dev Biol 2004, 116:93-107
21. Mackall CL Gress RE Thymic aging and T cell regeneration Immunol Rev 1997, 160:91-102 10.1111/j.1600-065X.1997.tb01030.x 9476668
22. Antony PA Piccirillo CA Akpinarli A Finkelstein SE Speiss PJ Surman DR Palmer DC Chan CC Klebanoff CA Overwijk WW Rosenberg SA Restifo NP CD8+ cell immunity against a persisting tumor/self-antigen requires CD4+ T cells and fails in the presence of naturally occuring T regulatory cells J Immunol 2005, 174:2591-2601 1403291 15728465
23. Bass KK Mastrangelo MJ Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer Cancer Immunol Immunother 1998, 47:1-12 10.1007/s002620050498 9755873
24. Powell DJ Jr Dudley ME Hogan KA Wunderlich JR Rosenberg SA Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion J Immunol 2006, 177:6527-6539 17056585
25. Jaffee EM Hruban RH Biedrzycki B Laheru D Schepers K Sauter PR Goemann M Coleman J Grochow L Donehower RC Lillemoe KD O'Reilly S Abrams RA Pardoll DM Cameron JL Yeo CJ Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation J Clin Oncol 2001, 19:145-156 11134207
26. Appay V Voelter V Rufer N Reynard S Jandus C Gasparini D Lienard D Speiser DE Schneider P Cerottini JC Romero P Leyvraz S Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma J Immunother 2007, 30:240-250 10.1097/ 01.cji.0000211332.68643.98 17471171
27. Powell A Creaney J Broomfield S Van Bruggen I Robinson B Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma Lung Cancer 2006, 52:189-197 10.1016/j.lungcan.2006.01.007 16563560
28. Nemunaitis J Jahan T Ross H Sterman D Richards D Fox B Jablons D Aimi J Lin A Hege K Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer Cancer Gene Therapy 2006, 13:555-562 10.1038/sj.cgt.7700922 16410826
29. Serafini P Carbley R Noonan KA Tan G Bronte V Borrello I High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells Cancer Res 2004, 64:6337-6343 10.1158/0008-5472.CAN-04-0757 15342423